Growth Picks
2026 Small-Cap Biotech Catalysts: Goldman’s Top Picks
As 2025 wraps up, investors are eyeing a blockbuster year for small-cap biotechs. With major Phase 2 data, pivotal trial...
28/12/2025
2 views